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Abstract 
 
Background 
Mortality due to cirrhosis has tripled over the last 30 years in the UK. However, we 
lack adequate, contemporary, population-based estimates of the excess mortality 
patients are at risk of compared with the general population. 
 
Aim 
To determine the overall survival in patients with cirrhosis compared with the general 
population taking into account the effects of severity and aetiology of disease, and 
comorbidity. 
 
Methods 
In a cohort study, we identified 4537 people with cirrhosis and a control cohort of 
44,403 patients, matched by age, sex and general practice from the UK General 
Practice Research Database between June 1987 and April 2002.   
 
Results 
Patients with compensated cirrhosis had a near 6-fold (Hazard Ratio 5.8 95% CI [5.5-
6.1]) increased risk of death while those with decompensated cirrhosis had a near 
10-fold (HR 9.7 95% CI [8.9-10.6]) increased risk compared with the general 
population.  Alcoholic cirrhosis conferred a worse prognosis than non-alcohol related 
cirrhosis both in the first year following diagnosis and subsequently.  
 
Conclusion 
Having a diagnosis of cirrhosis confers a substantial increased mortality risk 
compared with the general population, even for those with compensated disease, 
with 5-year survival between that seen for breast and colorectal cancer.
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Introduction 
Mortality from liver cirrhosis in the UK has tripled over the last three decades and 
recent estimates of the incidence of cirrhosis suggest that this is also increasing 
raising the spectre of escalating morbidity and mortality in the future.[1] [2] [3]  There 
are several studies which report the number of people who die with a recording of 
cirrhosis on their death certificate and the trends in such data but there is little 
information about the mortality experience of patients with cirrhosis.   
Few contemporary studies have been able to take a truly population based approach 
(i.e. including those patients who are not admitted to hospital) to determining the 
mortality experience with the general population taking into account both comorbid 
conditions and the aetiology and severity of the liver disease.  
 
Perhaps the most commonly referenced figures in the literature looking at the 
mortality experience of patients with cirrhosis are those based on 1155 consecutive 
patients admitted to a single hospital in Sicily during the 1970s and 1980s.[4]  More 
recently, two studies have approached the issue of survival in cirrhosis using large 
hospital-based databases.[5] [6]  Thus, most of our knowledge on the mortality 
experience of people with cirrhosis is from a few highly selected populations which 
may not be broadly representative of the whole population of people with cirrhosis i.e. 
including those who do not require admission to hospital with their disease.     
 
Additionally, we do not have precise and contemporary estimates of the all-cause 
mortality at a population level of people with cirrhosis taking into account the 
compensated or decompensated state of the patient. Nor have we previously been 
able to make the necessary comparisons with the general population to understand 
the magnitude of the burden of this disease.  Indeed in a recent Health Technology 
Assessment systematic review it was claimed that existing data suggest that there is 
no excess mortality in those patients with compensated disease compared with the 
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general population[7] for the purposes of the cost-effectiveness analysis carried out.  
We have therefore taken the opportunity presented by prospectively recorded 
electronic primary care data from the UK to determine the overall survival in patients 
with cirrhosis compared with the general population while taking into account the 
effects of comorbidity and aetiology of disease.
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Methods  
Description of GPRD 
The General Practice Research Database (GPRD) is a longitudinal database 
consisting of anonymous computerised general practice records for over 13 million 
patients in the UK, including over 50 million patient years of usable data.  Practices 
are subjected to regular data quality checks and audits to maintain 95% inclusion of 
prescribing and morbidity events.  Data contained within this database are recorded 
through direct entry during general practice appointments and following 
communication from secondary care.  Data are coded based on both the Oxmis and 
Read medical coding dictionaries.  The GPRD has previously been shown to be 
broadly representative of the population of the UK.[8]  Approval was given by the 
Scientific and Ethical Committee of the GPRD for this study. 
 
Study population 
We obtained all records of patients with a diagnostic code for any liver disease within 
the GPRD between June 1987 and April 2002.  Patients aged 25 and over were 
selected based on the presence of a diagnostic or therapeutic code for cirrhosis, 
oesophageal varices and/or portal hypertension to represent a cohort of adult 
diagnosed cirrhosis.  This age cut-off was designed to avoid including patients who 
may have had the onset of cirrhosis under the age of 18.  Each patient was assigned 
a date of diagnosis of cirrhosis as the date of the first record of any of these codes.   
 
For each subject with liver disease, up to 10 general population controls were 
identified, matched by registration at the same general practice, by sex and by age 
(within 5 years).  Controls had to be alive and contributing data to the GPRD on the 
subject’s date of diagnosis of liver disease.  We excluded controls who subsequently 
had any diagnostic or therapeutic code for cirrhosis, oesophageal varices and/or 
portal hypertension within their own general practice record and those who were no 
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longer alive at their matched subject’s time of diagnosis with cirrhosis.  The date of 
diagnosis of cirrhosis was taken as the date of ‘pseudo-diagnosis’ for controls.   
 
Definitions 
Patients with cirrhosis were classified as being in a compensated or decompensated 
disease state at the date of diagnosis.  Cases with a code for ascites or 
gastrointestinal bleed or a prescription for spironolactone at or before the date of 
diagnosis were classified as being in a decompensated disease state with all other 
cases classified as compensated.   
Age was defined as age at date of diagnosis of cirrhosis for cirrhosis patients or date 
of pseudo-diagnosis for controls.  We categorised age as 25-44 years, 45-64 years 
and 65+ years.  Alcohol intake prior to diagnosis was defined as either teetotal, 
drinker or problem drinker based on Read and Oxmis codes.  Comorbidity was 
defined using the Charlson index, a weighted score shown to be strongly related to 
mortality.[9]  Weighted scores for mild or severe liver disease were not included 
within this analysis.   Patients’ records were examined for comorbidities prior to the 
date of diagnosis or pseudo-diagnosis and then an individual Charlson score was 
calculated.  Scores were categorised as 0, 1, or 2+ for the purposes of analysis.  
Body Mass Index (BMI) (kg/m2) was defined using data on height, weight and/or BMI 
recorded at least 1 year prior to diagnosis or pseudo-diagnosis.  This cut-off was 
used to try and ensure that weight loss due to undiagnosed disease did not change 
the initial BMI categorisation of subjects.   Presumed aetiology of cirrhosis of either 
alcohol-related, viral hepatitis, autoimmune liver disease, metabolic liver disease or 
other unspecified causes of cirrhosis was defined as described previously.[2]  Liver 
transplant was defined as a code for liver transplant subsequent to diagnosis of 
cirrhosis.  To define death we used a combination of the patient’s registration status 
within the GPRD and medical codes for death, with the earliest date of these being 
assigned as the date of death.   
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Statistical analyses 
Using Cox proportional hazards regression we modelled the hazard of death in the 
cirrhosis cohort compared with the control cohort employing an historical matched 
cohort study design.  Subjects with cirrhosis and controls entered the analysis period 
at the date of diagnosis or pseudo-diagnosis respectively and exited at the earliest of 
either date of death, date of moving out of their general practice or 30 April 2002, the 
last date of available data at the time of extraction.  We classified subjects with 
cirrhosis as either compensated at entry or decompensated at entry and 
subsequently modelled compensation as a time-varying covariate.  All models were 
adjusted, a priori, for age and sex.  Additional potential confounders (alcohol intake 
and comorbidity) were modelled as categorical variables (with a separate category 
for missing data) and included if they conferred a 10% adjustment in the hazard 
ratios seen. Following results from previous studies we planned to stratify by 
comorbidity at the design stage.  We split follow up time at one year and modelled 
hazard ratios during the first year following diagnosis and after one year.  We then 
split the population of cases into those with alcoholic cirrhosis and those with non-
alcohol related cirrhosis (all other causes and unspecified) and examined the 
mortality rates and adjusted hazard ratios compared with their matched controls for 
these two aetiologic groups.   
To minimise the potential for survival bias we ran the principal analysis again 
comparing mortality between compensated and decompensated cases and controls 
using only incident cases (as described previously[2]) and their matched controls.  To 
try to account for potential attrition bias the principal analysis was repeated using the 
earliest of date of death, deregistration or last recorded appointment in the GPRD as 
the exit-point for the analysis.     
Proportional hazards assumptions were checked using Schoenfeld residuals and log-
log plots.  Stata version 9.2 SE was used for all statistical analyses.  
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Results 
A total of 4537 patients aged 25 and over with a diagnosis of cirrhosis were 
identified, with a control cohort of 44,403 patients, matched by age, sex and general 
practice.  Median age at diagnosis was 56 years and 58% of subjects were male.  
Selected demographic, lifestyle and clinical characteristics of the study population 
are described in table 1.  Subjects with cirrhosis had more recorded comorbidity than 
the control cohort, but the majority of patients in both cohorts had no recorded 
comorbid illness (77.7% of patients with cirrhosis; 83.5% of control cohort).  
Substantially more subjects with cirrhosis than control subjects were recorded as 
being known problem drinkers prior to diagnosis / pseudo-diagnosis (30% vs. 2% 
respectively).   
 
The presumed aetiology of cirrhosis (taking into account medical records before and 
after diagnosis of cirrhosis) was recorded as alcoholic in just over half of our study 
population (50.9%).  Nearly two-fifths of our cirrhosis cohort had no specified 
aetiology (38.1%).  The majority of the patients with cirrhosis were identified at an 
early stage of cirrhosis with 68.9% being classified as compensated at entry.  Only 
2.3% of patients with cirrhosis went on to subsequently have a liver transplant 
recorded.   
 
Survival analysis 
In a total of 226,412 person-years of follow up (median length of follow-up 3.5 years) 
there were 1759 deaths in our cirrhosis cohort (38.8%) and 4033 deaths in the 
control cohort (9.1%).  Only a priori confounders of age and sex remained in the Cox 
regression model alongside the time-varying covariate to represent compensation / 
decompensation.  Overall, patients with cirrhosis had a hazard ratio for death 
(adjusted for age at diagnosis and sex) of 5.8 (95%CI [5.5, 6.1]) compared with the 
general population cohort.  A higher hazard ratio for death was seen for patients with 
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decompensated cirrhosis compared with the general population with a hazard ratio of 
9.7 (95% CI [8.9, 10.6]) (table 2) but a significantly higher hazard of death was still 
seen for patients with compensated cirrhosis; hazard ratio 4.7 (95% CI [4.4, 5.0]) 
compared with the general population.   
 
Overall survival at 1 and 5 years was 87.3% [95% CI 86.1%, 88.4%] and 66.5% [95% 
CI 64.5%, 68.5%] respectively in patients with compensated disease (Figure 2).  This 
contrasts with the much lower figures for patients with decompensated disease being 
at 1 year 75.0% [95% CI 72.5%, 77.3%] and at 5 years 45.4% [95% CI 42.1%, 
48.7%]. 
 
Mortality was higher during the first year than following as shown in table 3 but also 
remained substantial beyond one year.  Stratification by comorbidity showed that 
although the absolute mortality rates in those with no comorbidity were not as high as 
those with a large amount of comorbidity (Charlson score 2 or more) the adjusted 
hazard ratios for death were highest in this group.  This high relative risk of death 
was most noticeable in the first year following diagnosis with hazard ratios of 8.3 for 
the compensated cohort compared with the general population and 18.0 for the 
decompensated cohort.   
 
The absolute mortality rates of subjects with non-alcohol related cirrhosis was higher 
than that of subjects with alcoholic cirrhosis in the first year following diagnosis.  
Subsequent to the first year absolute mortality was similar in both groups.  However, 
the adjusted hazard ratios for mortality were much higher in the subjects with 
alcoholic cirrhosis compared to those with non-alcohol related cirrhosis both during 
the first year following diagnosis and subsequently.  This is a result of the absolute 
mortality rates seen in the control populations with the matched controls of subjects 
with alcoholic cirrhosis having a considerably lower mortality than the matched 
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controls of subjects with non-alcohol related cirrhosis.  This is principally mediated by 
the age-matching of controls. Patients with alcoholic cirrhosis had a significantly 
lower age at diagnosis (median age 52 years) than those with non-alcohol related 
cirrhosis (median age 63 years).   
 
Sensitivity analyses 
Running the analyses using slightly different cohort definitions led to no substantial 
differences in the adjusted hazard ratios for mortality either during the first year 
following diagnosis or subsequently.  
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Discussion 
We have shown that patients with cirrhosis including those not necessarily admitted 
to hospital have a substantially reduced survival.  Overall, patients with compensated 
cirrhosis have a nearly 6-fold increased risk of death compared with the general 
population and those with decompensated disease a nearly 10-fold increased risk.  
The considerable excess mortality we found is not explained by comorbidity in our 
cirrhotic cohort as even in those with no recorded comorbidity the hazard ratios for 
mortality are markedly increased compared with similarly matched general population 
controls.  Mortality relative to similar age- and sex-matched control cohorts was 
substantially greater for those subjects with alcoholic cirrhosis compared with 
subjects with non-alcohol related cirrhosis both in the first year following diagnosis 
and subsequently.   
 
By virtue of the electronic primary care data from a broad sample of primary care 
physicians at our disposal we have a constructed a large, representative, population-
based cohort of patients with cirrhosis with an appropriate general population 
comparison cohort.  These cohorts were identified reasonably recently (1987-2002) 
and therefore the results we have generated reflect the natural history of cirrhosis 
during this period.  As this is a population-based cohort, it is unlikely to have been 
affected by the variation in referrals and follow-ups seen in cohorts selected from 
secondary care. The size of the dataset we have used has allowed us to estimate 
mortality rates and adjusted hazard ratios for death stratifying by severity of disease, 
follow-up time and comorbidity.  We are confident based upon our previous validation 
study[2] (which showed the vast majority of patients with a recorded code for 
cirrhosis had available extra evidence from secondary care) that for the diagnosis of 
cirrhosis in general this coding within primary care is good. The additional clinical 
signs and symptoms of decompensation may not always be recorded as accurately 
however, unless they are of obvious clinical relevance to the GP.  Hence ascites is 
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probably symptomatic and therefore likely to be moderate to large-volume, clinically 
significant ascites (rather than that only identified by ultrasound).  It could be argued 
that the inclusion of both incident and prevalent cases in the cirrhosis cohort might 
lead to the introduction of survival bias as those cases who are prevalent have, by 
definition, already survived a particular length of time to still be included in the 
analysis.  However, estimates from the sensitivity analyses, including only incident 
cases, remained within the 95% confidence interval of the principal analysis.  The 
results reported including all incident and prevalent cases probably more accurately 
reflects the real world of clinical practice within the general population and allows for 
the communication of results that are directly valid to the patients being seen in 
primary care.     
Though the data available have allowed for an appropriate individually matched 
adjustment for some confounders (age and sex) it was not possible to examine the 
potential associations or modifying effects of other variables either because they 
were not available in the version of the GPRD used for this analysis e.g. socio-
economic status, or because there was such a high proportion of missing data e.g. 
BMI.  Data were also missing for alcohol status prior to diagnosis in over 90% of our 
cohort (66% of those with cirrhosis, 96% of control cohort).  There is a potential bias 
in the recording of alcohol status with a GP perhaps more likely to record the 
knowledge of a patient drinking heavily as this may affect their health, but conversely 
a patient may not be recorded as being teetotal unless they actually suffered from a 
condition that may be considered to be associated with alcohol use.  With such a 
high proportion of missing data it was not practical to model the survival analyses 
including only patients with available data.  When including missing data as a 
separate category alcohol status did not remain within the multivariable model.   
 
Our mortality analysis is perhaps best compared in detail with the two large studies 
on this subject and the most relevant previous study from the UK.  In 1981 Saunders 
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et al described the survival of 512 people admitted to hospital with cirrhosis in the 
West Midlands region of the UK between 1959 and 1976.[10]  Our 5-year survival 
estimates for compensated and decompensated cirrhosis are higher than theirs. This 
suggests that as expected some improvements that impact on death in the 
management of cirrhosis have occurred in the intervening 20 or so years, though 
some ascertainment bias in the earlier study with the most severe (and frequently 
hospitalised) cases being over represented is possible.  Our findings are analogous 
to the case fatality rates and standardized mortality ratios (SMR) reported from the 
Oxford region of the UK between 1968 and 1999 in people who had an admission to 
hospital with either chronic liver disease or cirrhosis.[6]  The 1-year SMR of 16.3 is 
substantially higher than the 1-year adjusted hazard ratios we have reported for 
patients with either compensated or decompensated disease.   Five-year survival 
was not calculated in their study. In comparison with the large Danish cohort study 
we again report better 1- and 5-year survival rates. [5]  The poorer survival estimates 
seen in these previous studies are unsurprising considering the hospital-based 
nature of the patients selected.  Our results are perhaps more widely generalisable to 
patients diagnosed with cirrhosis including those ambulatory patients who have not 
been admitted to hospital.   A similar difference in survival rates is seen when 
comparing our results to that of the widely quoted figures from D’Amico and 
colleagues of 6-year survival of 54% and 21% in patients with compensated and 
decompensated cirrhosis respectively.[11]  It is possible that the improvements in 
survival seen in our data are a reflection of improved management and outcomes of 
the complications of cirrhosis in the intervening decades or indeed that the high 
prevalence of hepatitis B virus in the Sicilian population means that we are 
comparing the mortality experiences from different aetiologies of cirrhosis in the two 
populations.  While other recent studies have reported on a variety of the outcomes 
we also examine here the differences in design and populations used, particularly the 
absence of ambulatory patients, render comparisons of limited use.[12] [13] [14] 
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In summary, our study has described the mortality associated with a diagnosis of 
cirrhosis in contemporary clinical practice. We have shown that overall mortality from 
cirrhosis remains high with a 5 year survival of around 60% which, while better than 
that observed over 20 years ago, is between the figures observed in people with 
colorectal and breast cancer.[15] The comparison with the general population puts 
our findings in wider context, demonstrating that even those with no recorded 
comorbidity and compensated disease have about a 5-fold increased risk of death, 
and we have been able to show that an alcoholic aetiology remains a particularly bad 
prognostic indicator.  We conclude that our results in conjunction with the previously 
observed increasing incidence of cirrhosis emphasise the growing threat of liver 
disease to public health.       
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Table 1 Demographic, lifestyle and clinical characteristics of cirrhosis cohort 
and general population cohort.   
 
Demographics / lifestyle factors 
 
Cirrhosis Cohort 
N=4537 
Control Cohort 
N=44,403 
Age at diagnosis (years) 
25-44 
45-64 
65+ 
 
 
 
943 (20.8) 
2256 (49.7) 
1338 (29.5) 
 
 
9403 (21.2) 
22219 (50.0) 
12781 (28.8) 
Sex 
Male 
Female 
 
 
2612 (57.6) 
1925 (42.4) 
 
25599 (57.7) 
18804 (42.3) 
Comorbidity† 
Charlson 0 
Charlson 1 
Charlson 2+ 
 
 
3525 (77.7) 
534 (11.8) 
478 (10.5) 
 
37085 (83.5) 
3704 (8.3) 
3614 (8.1) 
BMI 
Median BMI [IQR] (kg/m2) 
No recorded BMI 
 
25.5 [22.5, 28.7] 
3624 (80.0) 
 
25.3 [23.0, 28.2] 
33 294 (75.0) 
 
Alcohol status (prior to 
diagnosis) 
Teetotal 
Drinker 
Problem drinker 
No record  
 
 
 
2 (<0.1) 
170 (3.7) 
1378 (30.4) 
2987 (65.8) 
 
 
10 (<0.1) 
1007 (2.3) 
740 (1.7) 
42646 (96.0) 
Presumed aetiology‡ 
Alcoholic cirrhosis 
Viral hepatitis 
Autoimmune LD 
Metabolic LD 
Not classified 
 
 
2307 (50.8) 
238 (5.2) 
48 (1.1) 
354 (7.8) 
1730 (38.1) 
- 
Disease state at entry 
Compensated 
Decompensated 
 
 
3126 (68.9) 
1411 (31.1) 
- 
Liver Transplant (following 
diagnosis of cirrhosis) 
106 (2.3) 2 (<0.1) 
 
†Charlson index as per methods excluding liver disease.  Absence of coding for 
disease assumed to represent disease not present.   
‡NB As subjects were able to have more than one presumed aetiology, numbers in 
the table do not add up to 4537.   
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Table 2 Mortality rates and hazard ratios overall compared with the general 
population 
 
 
Events Person-years 
Mortality rate 
(per 1000 person years) 
Adjusted hazard 
ratio* [95%CI] 
Population controls 4033 209555 19.2 [18.7, 19.8] 1 
All cirrhosis 1759 16858 104.3 [99.6, 109.3] 5.8 [5.5, 6.1] 
Compensated 1115 13317 83.7 [79.0, 88.8] 4.7 [4.4, 5.0] 
Decompensated 644 3541 181.9 [168.4, 196.5] 9.7 [8.9, 10.6] 
* Adjusted for age and sex. 
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Figure 1 
Survival estimates for controls, subjects with compensated cirrhosis and 
subjects with decompensated cirrhosis.   
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Table 3. Mortality rates and hazard ratios during the first year and 
subsequently compared with the general population stratified by Charlson 
index and adjusted for age and sex 
 
 
 Mortality rate (per 1000) Adjusted hazard ratio  
 Control 
cohort 
Compensated 
cohort 
Decompensated 
cohort 
Compensated 
cohort 
Decompensated 
cohort 
During first year 
Overall 20.1 141.7 304.8 7.2 [6.4, 8.2] 15.1 [13.3, 17.2] 
 
Charlson 
score 
  
 
  
0 16.5 132.9 295.0 8.3 [7.2, 9.6] 18.0 [15.4, 21.0] 
1 28.6 152.9 266.1 5.7 [4.0, 8.3] 10.7 [7.4, 15.5] 
2+ 49.5 215.4 396.6 4.4 [3.2, 6.1] 8.2 [6.1, 11.1] 
 
Following first year 
Overall 19.0 69.2 129.1 4.0 [3.7, 4.3] 7.5 [6.7, 8.5] 
 
Charlson 
score 
  
 
  
0 16.4 65.8 121.7 4.4 [4.0, 4.8] 8.1 [7.0, 9.3] 
1 32.8 89.6 116.0 3.1 [2.4, 3.9] 5.0 [3.7, 6.9] 
2+ 43.0 90.5 201.6 2.3 [1.7, 3.0] 5.9 [4.4, 7.9] 
 
 
  
 19 
Table 4. Mortality rates and hazard ratios during the first year and 
subsequently compared with the general population stratified by aetiology and 
adjusted for age and sex 
 
 
 Events 
Person-
years 
Mortality rate 
(per 1000 person years) 
Adjusted hazard 
ratio* [95%CI] 
During first year     
Alcoholic cirrhosis     
Controls 271 20 344 13.3 [11.8, 15.0] - 
Compensated cirrhosis 174 1282 135.8 [117.0, 157.5] 10.5 [8.7, 12.7] 
Decompensated 
cirrhosis 
153 631 242.6 [207.1, 284.3] 17.7 [14.5, 21.6] 
Non-Alcohol-related 
cirrhosis 
    
Controls 525 19 257 27.3 [25.0, 29.7] - 
Compensated cirrhosis 204 1385 147.3 [128.4, 168.9] 5.7 [4.8, 6.7] 
Decompensated 
cirrhosis 
 
171 432 395.5 [340.5, 459.5] 13.7 [11.5, 16.3] 
Following first year     
Alcoholic cirrhosis     
Controls 1181 90 469 13.1 [12.3, 13.8] - 
Compensated cirrhosis 398 5285 75.3 [68.3, 83.1] 6.0 [5.4, 6.8] 
Decompensated 
cirrhosis 
190 1501 126.6 [109.8, 146.0] 11.0 [9.4, 12.8] 
Non-Alcohol-related 
cirrhosis 
    
Controls 2056 79 485 25.9 [24.8, 27.0] - 
Compensated cirrhosis 339 5365 63.2 [56.8, 70.3] 2.9 [2.6, 3.2] 
Decompensated 
cirrhosis 
130 977 133.0 [112.0, 158.0] 5.2 [4.4, 6.2] 
* Adjusted for age and sex. 
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